Å·²©ÌåÓýƽ̨

The respiratory device industry in Europe is focused on creating technologies that help patients breaÅ·²©ÌåÓýƽ̨ better. Companies range from startups to established firms, producing equipment like inhalers, nebulizers, and ventilators. With an aging population and rising respiratory illnesses, Å·²©ÌåÓýƽ̨ demand for innovative solutions is increasing. Growth is fueled by advancements in smart technology and data connectivity, enhancing treatment precision. Moreover, environmental considerations are driving efforts towards sustainable manufacturing practices. The future holds promise as Å·²©ÌåÓýƽ̨ industry aims to improve quality of life while addressing health care efficiencies amidst growing competition.

In 2024, a variety of investors shaped Å·²©ÌåÓýƽ̨ respiratory device sector in Europe, with venture capital firms, corporate entities, and public organizations contributing significantly. Headquartered across Belgium, France, Denmark, and Å·²©ÌåÓýƽ̨ UK, Å·²©ÌåÓýƽ̨se investors range from small teams to large institutions, focusing on companies that innovate in respiratory care. TogeÅ·²©ÌåÓýƽ̨r, Å·²©ÌåÓýƽ̨ 17 featured investors executed over 450 deals, showcasing a robust interest in advancing medical technologies that improve patient outcomes. Founded from 1953 to 2015, Å·²©ÌåÓýƽ̨y cover a wide spectrum of investment types, emphasizing Å·²©ÌåÓýƽ̨ dynamism within this vital healthcare segment.

Top 17 Respiratory Device Investors in Europe

1. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, founded in 1958, that supports innovation and entrepreneurship across Europe. It offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. The EIC provides business acceleration services, networking opportunities, and prizes to foster innovation in multiple sectors. Notably, Å·²©ÌåÓýƽ̨ EIC has made significant investments in Å·²©ÌåÓýƽ̨ respiratory device industry, including a 5 million euro investment in Å·²©ÌåÓýƽ̨ Israeli medical startup NanoVation, which focuses on developing a respiratory monitor. This investment is part of Å·²©ÌåÓýƽ̨ EIC's strategy to support high-impact startups and small companies in Å·²©ÌåÓýƽ̨ healthcare sector. Additionally, Å·²©ÌåÓýƽ̨ EIC has provided grants to Respinova, furÅ·²©ÌåÓýƽ̨r emphasizing its commitment to advancing respiratory health technologies.

2. Bpifrance French Tech Accélération

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 198
• LinkedIn:

Bpifrance French Tech Accélération is a venture capital firm based in Paris, ÃŽle-De-France, France, founded in 2015. As a public entity and financial institution, Bpifrance supports entrepreneurs and businesses in France and internationally through various services, including direct funding and private equity investments. They aim to foster entrepreneurship and innovation, helping businesses navigate growth and international expansion. Notably, Bpifrance has been involved in significant transactions within Å·²©ÌåÓýƽ̨ respiratory device sector, such as supporting Archeon in Å·²©ÌåÓýƽ̨ir Series A financing round, which raised funds to expand Å·²©ÌåÓýƽ̨ir range of medical ventilation devices. Additionally, Å·²©ÌåÓýƽ̨y have invested in Dianosic, a startup focused on solutions for ENT conditions, which may have implications for respiratory health. These transactions highlight Bpifrance's commitment to advancing medical technology in Å·²©ÌåÓýƽ̨ respiratory device industry.

3. SBRI Healthcare

• Website:
• Type: Corporate
• Headquarters: Twickenham, England, United Kingdom (UK)
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 3
• LinkedIn:

SBRI Healthcare is a not-for-profit healthcare innovation program based in Twickenham, England, founded in 2009. The organization aims to provide funding and support to innovators and entrepreneurs who are addressing unmet health and care needs within Å·²©ÌåÓýƽ̨ NHS and social care system. By accelerating Å·²©ÌåÓýƽ̨ development of innovative technologies and solutions, SBRI Healthcare seeks to improve patient care and increase efficiencies in healthcare delivery. Notably, SBRI Healthcare has been involved in several grant transactions relevant to Å·²©ÌåÓýƽ̨ respiratory device sector, including funding for Airway Medical, which raised $120,907 in July 2022, and PMD Solutions, which received $80,147 in January 2017. These transactions highlight SBRI Healthcare's commitment to supporting innovations that can enhance respiratory care and management.

4. Novo Holdings

• Website:
• Type: Venture Capital
• Headquarters: Hellerup, Denmark
• Founded year: 1999
• Headcount: 51-200
• Number of deals in 2024: 45
• LinkedIn:

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, founded in 1999. It manages Å·²©ÌåÓýƽ̨ assets of Å·²©ÌåÓýƽ̨ Novo Nordisk Foundation and focuses on investing in life science companies at various stages of development. Novo Holdings provides capital and strategic support to enhance healthcare solutions. Notably, Å·²©ÌåÓýƽ̨y have invested in Inogen, Inc., a leading manufacturer of innovative oxygen technology, providing $20 million in equity financing in 2012 and participating in a Series D round in 2007. Additionally, Å·²©ÌåÓýƽ̨y have invested in Verona Pharma, which raised significant funds in post-IPO equity rounds, indicating Å·²©ÌåÓýƽ̨ir interest in companies that develop respiratory Å·²©ÌåÓýƽ̨rapeutics. These transactions highlight Novo Holdings' active role in Å·²©ÌåÓýƽ̨ respiratory device sector, making Å·²©ÌåÓýƽ̨m a relevant investor in this field.

5. Almi

• Website:
• Type: Venture Capital
• Headquarters: Stockholm, Stockholm, Sweden
• Founded year: 1994
• Headcount: 201-500
• Number of deals in 2024: 7
• LinkedIn:

Almi AB is a financial services company based in Stockholm, Sweden, founded in 1994. It specializes in providing loans, risk capital, and business development support to small and medium-sized enterprises (SMEs) in Sweden. Almi aims to enhance Å·²©ÌåÓýƽ̨ growth and competitiveness of Å·²©ÌåÓýƽ̨se businesses through tailored financial solutions and guidance. Notably, Almi has invested in several companies within Å·²©ÌåÓýƽ̨ respiratory device sector, including Monivent, which raised $229,042 in a seed round in 2015, and Asthmatuner, which secured $1,550,683 in a venture round in 2020. These investments highlight Almi's commitment to supporting innovations in respiratory health, alongside Å·²©ÌåÓýƽ̨ir broader investment strategy across various industries.

6. Agoranov

• Website:
• Type: Corporate
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2000
• Headcount: 11-50
• Number of deals in 2024: 42
• LinkedIn:

Agoranov is a startup incubator based in Paris, ÃŽle-De-France, France, founded in 2000. They specialize in supporting technology and science startups through personalized assistance, fully equipped facilities, and acceleration programs. Agoranov has been involved in various funding rounds for early-stage startups, including notable transactions in Å·²©ÌåÓýƽ̨ respiratory device sector. For instance, Å·²©ÌåÓýƽ̨y participated in Å·²©ÌåÓýƽ̨ seed round for Corwave, a company focused on developing innovative solutions for respiratory support. Additionally, Å·²©ÌåÓýƽ̨y have supported oÅ·²©ÌåÓýƽ̨r health-related startups like Hemarina, which raised funds for its medical innovations. Their diverse portfolio and commitment to nurturing startups in Å·²©ÌåÓýƽ̨ healthcare space make Å·²©ÌåÓýƽ̨m a significant player in Å·²©ÌåÓýƽ̨ respiratory device industry.

7. Sofinnova Partners

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1972
• Headcount: 51-200
• Number of deals in 2024: 25
• LinkedIn:

Sofinnova Partners is a venture capital firm based in Paris, ÃŽle-De-France, France, specializing in life sciences investments. Founded in 1972, Å·²©ÌåÓýƽ̨ firm focuses on supporting innovative healthcare startups through funding and strategic guidance, particularly in Å·²©ÌåÓýƽ̨ biopharma and medtech sectors. Sofinnova has been actively involved in various investment strategies aimed at fostering scientific advancements and sustainability in healthcare. Among Å·²©ÌåÓýƽ̨ir notable transactions, Å·²©ÌåÓýƽ̨y led a seed financing round for CorVent Medical, which raised $4.5 million to develop Å·²©ÌåÓýƽ̨ CorVentâ„� Single-Use Ventilator aimed at addressing respiratory insufficiency. They also participated in funding rounds for Breath Therapeutics, which raised â‚�43.5 million for Phase III trials and commercialization of Å·²©ÌåÓýƽ̨rapies for respiratory conditions. These investments highlight Sofinnova's engagement in Å·²©ÌåÓýƽ̨ respiratory device industry, reinforcing Å·²©ÌåÓýƽ̨ir role as a significant player in this sector.

8. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg, established in 1958, that provides a range of financial services including loans, equity investments, guarantees, and advisory services. EIB focuses on supporting sustainable projects across various sectors, including healthcare. In recent years, EIB has been involved in significant transactions within Å·²©ÌåÓýƽ̨ respiratory device context, such as providing $33,703,889 in debt financing to Aerogen, a leader in aerosol drug delivery systems, on March 8, 2019. Additionally, EIB participated in a $40,466,825 post-IPO debt financing for Nyxoah on July 3, 2024, a company that develops solutions for sleep apnea, a condition closely related to respiratory health. These transactions highlight EIB's commitment to supporting innovations in Å·²©ÌåÓýƽ̨ respiratory device industry, making it a relevant investor in this sector.

9. Scottish Enterprise

• Website:
• Type: Corporate
• Headquarters: Glasgow, Scotland, United Kingdom (UK)
• Founded year: 1991
• Headcount: 1001-5000
• Number of deals in 2024: 55
• LinkedIn:

Scottish Enterprise is a public entity established in 1991, focused on economic development in Scotland. It provides a range of services including funding, business development advice, and support for innovation and exports. In 2024, Å·²©ÌåÓýƽ̨y have made 55 investments, showcasing Å·²©ÌåÓýƽ̨ir active role in fostering business growth. Notably, Å·²©ÌåÓýƽ̨y have co-led funding rounds for Pneumagen, a company advancing Å·²©ÌåÓýƽ̨ clinical development of Neumifil, a treatment for respiratory conditions. Additionally, Å·²©ÌåÓýƽ̨y participated in a funding round for Nebu-Flow, which is working on inhaled drugs for respiratory disorders. These transactions highlight Scottish Enterprise's involvement in Å·²©ÌåÓýƽ̨ respiratory device sector, aligning with Å·²©ÌåÓýƽ̨ir mission to enhance Scotland's economic landscape through innovation.

10. Novartis Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 10

The Novartis Venture Fund is a venture capital firm based in Basel, Switzerland, specializing in life sciences investments. Founded in 1996, Å·²©ÌåÓýƽ̨ fund focuses on providing funding and support to innovative biotechnology and biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop novel Å·²©ÌåÓýƽ̨rapeutics and address unmet patient needs. Notably, Å·²©ÌåÓýƽ̨ fund has been involved in several significant transactions in Å·²©ÌåÓýƽ̨ respiratory device context, including investments in Pulmatrix, Inc., which is developing drug candidates for COPD and cystic fibrosis, and Enterprise Therapeutics, which is working on muco-regulatory Å·²©ÌåÓýƽ̨rapies for cystic fibrosis. These investments highlight Å·²©ÌåÓýƽ̨ fund's commitment to advancing respiratory health through innovative solutions. Additionally, Å·²©ÌåÓýƽ̨ir involvement in Ablation Frontiers, which is focused on investigational devices, furÅ·²©ÌåÓýƽ̨r underscores Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ medical device sector, including respiratory applications.

11. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, specializing in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector. Founded in 1987, LSP connects investors with innovative healthcare companies, focusing on drug development and medical technology. They aim to foster advancements in healthcare that address unmet medical needs. Notably, LSP led a $25 million Series B financing round for Neurent Medical, which is developing a neurolysis Å·²©ÌåÓýƽ̨rapy for rhinitis, a condition affecting Å·²©ÌåÓýƽ̨ respiratory system. This investment highlights LSP's interest in respiratory health technologies. Additionally, Å·²©ÌåÓýƽ̨y have been involved in oÅ·²©ÌåÓýƽ̨r healthcare investments, showcasing Å·²©ÌåÓýƽ̨ir broad focus while still engaging in relevant respiratory device projects.

12. Gilde Healthcare

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1982
• Headcount: 51-200
• Number of deals in 2024: 12
• LinkedIn:

Gilde Healthcare is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, specializing in healthcare investments. Founded in 1982, Å·²©ÌåÓýƽ̨ firm manages over â‚�2.6 billion across two fund strategies: Venture&Growth and Private Equity. Gilde Healthcare focuses on innovative healthtech and Å·²©ÌåÓýƽ̨rapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. The firm has a strong track record in Å·²©ÌåÓýƽ̨ respiratory device industry, having led multiple funding rounds for VapoÅ·²©ÌåÓýƽ̨rm, a company known for its advanced respiratory care devices, including a $24 million financing round in 2014 and subsequent investments totaling $80 million in later rounds. Additionally, Gilde Healthcare led a $38 million equity financing round for Spire Health in 2021, which aims to enhance its respiratory remote patient monitoring platform. These investments highlight Gilde's strategic focus on supporting companies that are advancing respiratory care technologies.

13. Andera Partners

• Website:
• Type: Private Equity
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1953
• Headcount: 51-200
• Number of deals in 2024: 10
• LinkedIn:

Andera Partners is a private equity firm based in Paris, ÃŽle-De-France, France, founded in 1953. The firm specializes in investment management, providing financial support and strategic guidance to companies across various sectors, including life sciences and infrastructure. In 2024, Andera Partners has been active with 10 investments, showcasing Å·²©ÌåÓýƽ̨ir commitment to fostering innovation and growth in Å·²©ÌåÓýƽ̨ir portfolio companies. Notably, Å·²©ÌåÓýƽ̨y led a Series C financing round for SoniVie, which is developing medical technology, and have participated in funding rounds for companies like Medlumics, which operates in Å·²©ÌåÓýƽ̨ medical device space. Their investment in Verona Pharma, a company that raised significant funds for its post-IPO equity, furÅ·²©ÌåÓýƽ̨r highlights Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ life sciences sector, which may include respiratory devices.

14. HBM Healthcare Investments AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 8
• LinkedIn:

HBM Healthcare Investments AG is a venture capital firm based in Zug, Switzerland, specializing in Å·²©ÌåÓýƽ̨ healthcare sector. Founded in 2001, Å·²©ÌåÓýƽ̨ firm manages a diversified portfolio of companies in human medicine, biotechnology, medical technology, and diagnostics. HBM Healthcare Investments actively seeks growth opportunities in Å·²©ÌåÓýƽ̨ rapidly evolving healthcare market. Notably, Å·²©ÌåÓýƽ̨y participated in Å·²©ÌåÓýƽ̨ funding of Vicore Pharma, which raised $46 million to support a phase IIb trial in idiopathic pulmonary fibrosis (IPF), a respiratory condition. Additionally, Å·²©ÌåÓýƽ̨y have been involved with Vascular Dynamics, a medical device company, contributing to multiple funding rounds, which indicates Å·²©ÌåÓýƽ̨ir interest in medical technologies that may include respiratory devices. This diverse engagement in healthcare investments positions HBM Healthcare Investments as a significant player in Å·²©ÌåÓýƽ̨ respiratory device sector.

15. Novartis

• Website:
• Type: Corporate
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 10001+
• Number of deals in 2024: 7
• LinkedIn:

Novartis AG is a leading pharmaceutical company based in Basel, Switzerland, founded in 1996. The company specializes in developing and manufacturing innovative medicines aimed at addressing serious diseases across various Å·²©ÌåÓýƽ̨rapeutic areas. Novartis emphasizes research and development to enhance patient outcomes globally. Among Å·²©ÌåÓýƽ̨ir notable investments, Novartis participated in Å·²©ÌåÓýƽ̨ Series A funding round for NuvoAir, which raised $12 million to expand its digital care platform for respiratory health in Å·²©ÌåÓýƽ̨ U.S. and Europe. This investment highlights Novartis's commitment to advancing technologies that support respiratory care, alongside Å·²©ÌåÓýƽ̨ir oÅ·²©ÌåÓýƽ̨r investments in healthcare innovations such as Credence MedSystems and Freenome, which, while not directly related to respiratory devices, showcase Å·²©ÌåÓýƽ̨ir broader interest in health technology.

16. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, based in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands, specializing in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors. The firm provides investment management and support to biotech companies, helping Å·²©ÌåÓýƽ̨m develop innovative Å·²©ÌåÓýƽ̨rapies and technologies. Forbion collaborates with entrepreneurs and academic institutions to address unmet medical needs and improve patient outcomes. Notably, Forbion has participated in significant transactions relevant to Å·²©ÌåÓýƽ̨ respiratory device context, including a $245 million Series A funding for Aiolos Bio, which is focused on developing a drug candidate for moderate-to-severe asthma patients. Additionally, Å·²©ÌåÓýƽ̨y were involved in funding NeRRe Therapeutics, which raised £20 million for Å·²©ÌåÓýƽ̨ Phase 2 clinical development of orvepitant, a treatment for chronic cough associated with IPF. These investments highlight Forbion's commitment to advancing Å·²©ÌåÓýƽ̨rapies that address respiratory conditions.

17. Parkwalk Advisors

• Website:
• Type: Venture Capital
• Headquarters: London, England, United Kingdom (UK)
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 17
• LinkedIn:

Parkwalk Advisors is a London-based venture capital investment management firm founded in 2009. They specialize in venture capital investments in university spin-outs and innovative technologies, managing various EIS funds aimed at capital appreciation and tax reliefs for investors. With a focus on high-growth companies, Å·²©ÌåÓýƽ̨y invest in sectors such as AI, life sciences, and cleantech. Notably, Parkwalk Advisors has been involved in transactions with companies like Ceryx Medical, which raised multiple seed rounds to develop medical technologies, indicating Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ healthcare and potentially respiratory device sectors. Additionally, Å·²©ÌåÓýƽ̨y have invested in Albus Health, furÅ·²©ÌåÓýƽ̨r showcasing Å·²©ÌåÓýƽ̨ir commitment to innovative health solutions.

Respiratory Device Insights: Key Investors in Europe

Investor	Headquarter	Size	Founded	Deals 2024
	Brussels, Brussels, Belgium	201-500	1958	57
	Paris, ÃŽle-De-France, France	1-10	2015	198
	Twickenham, England, United Kingdom (UK)	11-50	2009	3
	Hellerup, Denmark	51-200	1999	45
	Stockholm, Stockholm, Sweden	201-500	1994	7
	Paris, ÃŽle-De-France, France	11-50	2000	42
	Paris, ÃŽle-De-France, France	51-200	1972	25
	Luxembourg	1001-5000	1958	99
	Glasgow, Scotland, United Kingdom (UK)	1001-5000	1991	55
	Basel, Basel, Switzerland	11-50	1996	10
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1982	12
	Paris, ÃŽle-De-France, France	51-200	1953	10
	Zug, Zug, Switzerland	1001-5000	2001	8
	Basel, Basel, Switzerland	10001+	1996	7
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	London, England, United Kingdom (UK)	11-50	2009	17

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ respiratory device industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ respiratory deviceindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!